GO
Loading...

Amgen, Cytokinetics Announce Heart Drug Alliance

Amgen and Cytokinetics announced a collaboration to develop heart failure drugs that could yield smaller Cytokinetics more than $600 million depending on development success.

Symbol
Price
 
Change
%Change
EME
---
CYTK
---

Cytokinetics is receiving an up-front fee of $42 million. In addition, Amgen has purchased nearly 3.5 million shares of Cytokinetics at $9.47 a share, or an aggregate price of about $33 million. Cytokinetics shares closed last Friday at $7.48.

Amgen gained an option to participate in development and commercialization of Cytokinetics' lead drug candidate arising from the heart-failure program, CK-1827452, which recently completed two Phase 1 clinical trials.

Cytokinetics also may receive milestone payments of up to $600 million on CK-1827452 and other products arising from the research as well as royalties, the companies said.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    To learn more about how we use your information,
    please read our Privacy Policy.
    › Learn More

Don't Miss

U.S. Video